Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-26T03:35:32.659Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of N-acetylcysteine on substance use in bipolar disorder: a randomised placebo-controlled clinical trial

Published online by Cambridge University Press:  24 June 2014

Michelle Bernardo ,
Seetal Dodd ,
Clarissa S. Gama ,
David L Copolov ,
Olivia Dean ,
Kristy Kohlmann ,
Susan Jeavons ,
Ian Schapkaitz ,
Murray Anderson-Hunt  and
Ashley I Bush
...Show all authors
Michelle Bernardo
Affiliation:
Department of Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, Geelong, Australia
Seetal Dodd*
Affiliation:
Department of Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, Geelong, Australia
Clarissa S. Gama
Affiliation:
Laboratório de Psiquiatria Molecular, Centro de Pesquisas, Hospital de Clínicas de Porto Alegre, Brazil
David L Copolov
Affiliation:
Mental Health Research Institute, Parkville, Australia Monash University, Clayton, Australia
Olivia Dean
Affiliation:
Department of Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, Geelong, Australia Mental Health Research Institute, Parkville, Australia
Kristy Kohlmann
Affiliation:
Department of Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, Geelong, Australia Mental Health Research Institute, Parkville, Australia
Susan Jeavons
Affiliation:
Mental Health Research Institute, Parkville, Australia
Ian Schapkaitz
Affiliation:
Mental Health Research Institute, Parkville, Australia
Murray Anderson-Hunt
Affiliation:
Mental Health Research Institute, Parkville, Australia
Ashley I Bush
Affiliation:
Mental Health Research Institute, Parkville, Australia
Michael Berk
Affiliation:
Department of Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, Geelong, Australia Orygen Research Centre, Parkville, Australia Mental Health Research Institute, Parkville, Australia
*
Dr Seetal Dodd Department of Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, PO Box 281, Geelong 3220, Australia. Tel: +61 3 5226 7666; Fax: +61 3 5246 5165; E-mail: seetald@barwonhealth.org.au
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To evaluate the effect of N-acetylcysteine (NAC) on substance use in a double-blind, placebo-controlled trial of NAC in bipolar disorder. It is hypothesised that NAC will be superior to placebo for reducing scores on the Clinical Global Impressions scale for Substance Use (CGI-SU).

Methods:

Participants were randomised to 6-months of treatment with 2 g/day NAC (n = 38) or placebo (n = 37). Substance use was assessed at baseline using the Habits instrument. Change in substance use was assessed at regular study visits using the CGI-SU.

Results:

Amongst the 75 participants 78.7% drank alcohol (any frequency), 45.3% smoked tobacco and 92% consumer caffeine. Other substances were used by fewer than six participants. Caffeine use was significantly lower for NAC-treated participants compared with placebo at week 2 of treatment but not at other study visits.

Conclusion:

NAC appeared to have little effect on substance use in this population. A larger study on a substance using population will be necessary to determine if NAC may be a useful treatment for substance use.

Keywords

alcoholbipolar disordercaffeineclinical trialN-acetyl cysteinesmokingsubstance use
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 21 , Issue 5 , October 2009 , pp. 239 - 245
Copyright
Copyright © 2009 John Wiley & Sons A/S

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Berk, M, Dodd, S, Berk, L.The management of bipolar disorder in primary care: a review of existing and emerging therapies. Psychiatry Clin Neurosci 2005;59:229–239. CrossRefGoogle ScholarPubMed
Regier, DA, Farmer, ME, Rae, DSet al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511–2518. CrossRefGoogle ScholarPubMed
Goldberg, JF, Garno, JL, Leon, AC, Kocsis, JH, Portera, L.A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry 1999;60:733–740. CrossRefGoogle ScholarPubMed
Dossing, M, Sonne, J.Drug-induced hepatic disorders. Incidence, management and avoidance. Drug Saf 1993;9:441–449. CrossRefGoogle ScholarPubMed
Cassidy, F, Ahearn, EP, Carroll, BJ.Substance abuse in bipolar disorder. Bipolar Disord 2001;3:181–188. CrossRefGoogle ScholarPubMed
Castro, AA, Moretti, M, Casagrande, TSet al. Neuropeptide S produces hyperlocomotion and prevents oxidative stress damage in the mouse brain: a comparative study with amphetamine and diazepam. Pharmacol Biochem Behav 2009;91:636–642. CrossRefGoogle ScholarPubMed
Reddy, RD, Yao, JK.Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 1996;55:33–43. CrossRefGoogle ScholarPubMed
Ozcan, ME, Gulec, M, Ozerol, E, Polat, R, Akyol, O.Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004;19:89–95. CrossRefGoogle ScholarPubMed
Machado-Vieira, R, Andreazza, AC, Viale, CIet al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007;421:33–36. CrossRefGoogle ScholarPubMed
Andreazza, AC, Cassini, C, Rosa, ARet al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007;41:523–529. CrossRefGoogle ScholarPubMed
Frey, BN, Andreazza, AC, Kunz, Met al. Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:283–285. CrossRefGoogle ScholarPubMed
Grignon, S, Chianetta, JM.Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:365–369. CrossRefGoogle ScholarPubMed
Gama, CS, Berk, M, Andreazza, AC, Kapczinski, F, Belmonte-de-Abreu, P.Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation. Rev Bras Psiquiatr 2008;30:337–340. CrossRefGoogle ScholarPubMed
Gama, CS, Salvador, M, Andreazza, AC, Kapczinski, F, Silva Belmonte-de-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:512–515. CrossRefGoogle ScholarPubMed
Gama, CS, Salvador, M, Andreazza, ACet al. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neurosci Lett 2008;433:270–273. CrossRefGoogle ScholarPubMed
Kalivas, PW, O’Brien, C.Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 2008;33:166–180. CrossRefGoogle ScholarPubMed
Stork, C, Renshaw, PF.Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005;10:900–919. CrossRefGoogle ScholarPubMed
Wozniak, B, Musialkiewicz, D, Wozniak, Aet al. Lack of changes in the concentration of thiobarbituric acid-reactive substances (TBARS) and in the activities of erythrocyte antioxidant enzymes in alcohol-dependent patients after detoxification. Med Sci Monit 2008;14:CR32–CR36. Google ScholarPubMed
Baker, DA, McFarland, K, Lake, RWet al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neuroscience 2003;6:743–749. CrossRefGoogle ScholarPubMed
Moran, MM, McFarland, K, Melendez, RI, Kalivas, PW, Seamans, JK.Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci 2005;25:6389–6393. CrossRefGoogle ScholarPubMed
McFarland, K, Lapish, CC, Kalivas, PW.Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 2003;23:3531–3537. Google ScholarPubMed
Madayag, A, Lobner, D, Kau, KSet al. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. J Neurosci 2007;27:13968–13976. CrossRefGoogle ScholarPubMed
Zhou, W, Kalivas, PW.N-acetylcysteine reduces extinction responding and induces enduring reductions in cue- and heroin-induced drug-seeking. Biol Psychiatry 2008;63:338–340. CrossRefGoogle ScholarPubMed
Grant, JE, Kim, SW, Odlaug, BL.N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007;62:652–657. CrossRefGoogle ScholarPubMed
Burgunder, JM, Varriale, A, Lauterburg, BH.Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 1989;36:127–131. CrossRefGoogle ScholarPubMed
Holdiness, MR.Clinical pharmokinetics of N-acetylcysteine. Clincal Pharmokinetics 1991;20:123–134. CrossRefGoogle Scholar
Dean, O, van den Buuse, M, Copolov, DL, Berk, M, Bush, AI.N-acetylcysteine treatment inhibits depletion of brain glutathione levels in rats: implications for schizophrenia. Int J Neuropsychopharmacol 2004;7:S262. Google Scholar
Andreassen, OA, Dedeoglu, A, Klivenyi, P, Beal, MF, Bush, AI.N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. NeuroReport 2000;11:2491–2493. CrossRefGoogle Scholar
Louwerse, ES, Weverling, GJ, Bossuyt, PM, Meyjes, FE, De Jong, JM.Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995;52:559–564. CrossRefGoogle ScholarPubMed
Rothstein, JD, Bristol, LA, Hosler, B, Brown, RH Jr, Kuncl, RW.Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci U S A 1994;91:4155–4159. CrossRefGoogle ScholarPubMed
Koppal, T, Drake, J, Butterfield, DA.In vivo modulation of rodent glutathione and its role in peroxynitrite-induced neocortical synaptosomal membrane protein damage. Biochimica et Biophysica Acta 1999;1453:407–411. CrossRefGoogle ScholarPubMed
Mayer, M, Noble, M.N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci U S A 1994;91:7496–7500. CrossRefGoogle ScholarPubMed
Staal, FJ, Anderson, MT, Herzenberg, LA.Redox regulation of activation of NF-kappa B transcription factor complex: effects of N-acetylcysteine. Methods Enzymol 1995;252:168–174. CrossRefGoogle ScholarPubMed
Ferrari, G, Yan, CY, Greene, LA.N-acetylcysteine (D- and L-stereoisomers) prevents apoptotic death of neuronal cells. J Neurosci 1995;15:2857–2866. Google Scholar
Berk, M, Copolov, D, Dean, Oet al. N-acetyl cysteine as a glutathione precursor for schizophrenia–a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008;64:361–368. CrossRefGoogle ScholarPubMed
Berk, M, Copolov, DL, Dean, Oet al. N-acetyl cysteine for depressive symptoms in bipolar disorder–a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;64:468–475. CrossRefGoogle ScholarPubMed
Guy, W.ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch, 1976. Google Scholar